+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06162221

Evaluation of RASON Inhibitors Alone or with Standard Therapy in Patients with Advanced RAS-Mutated Non-Small Cell Lung Cancer

Led by Revolution Medicines, Inc. · Updated on 2026-10-19

616

Participants Needed

98

Research Sites

78 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of new RASON inhibitors in patients with advanced RAS-mutated non-small cell lung cancer NSCLC and other solid tumors. The study focuses on patients with specific KRAS or RAS mutations and uses an open-label platform design including multiple subprotocols to test different drug combinations and monotherapies. Participants are assigned to one of four subprotocols testing various combinations of oral RASON inhibitorsRMC-6291, RMC-6236, and RMC-9805with or without pembrolizumab and chemotherapy. Subprotocols A, B, and C have two parts dose exploration and dose expansion, while Subprotocol D consists of one part. Treatments include oral tablets and intravenous infusions given in specific schedules, such as twice daily BID or once daily QD dosing for oral drugs and every three weeks Q3W for infusions. Throughout the study, participants undergo regular monitoring for adverse events, dose limiting toxicities, and drug concentration levels up to 21 weeks, with antitumor responses and duration of response followed for up to five years. Safety and effectiveness assessments, including laboratory tests and clinical evaluations, are conducted during treatment and long-term follow-up to understand the drugs effects and tolerability in this patient population.

CONDITIONS

Brief Title

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Research Team

R

Revolution Medicines

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here